000 01581 a2200445 4500
005 20250516173258.0
264 0 _c20140313
008 201403s 0 0 spa d
022 _a2173-9110
024 7 _a10.4321/S1135-57272013000400004
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBonet Pla, Alvaro
245 0 0 _a[Dabigatran versus acenocumarol for the prevention of stroke in atrial fibrillation: budget impact analysis in one health department in Spain].
_h[electronic resource]
260 _bRevista espanola de salud publica
_c
300 _a331-42 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAcenocoumarol
_xadministration & dosage
650 0 4 _aAged
650 0 4 _aAnticoagulants
_xadministration & dosage
650 0 4 _aAtrial Fibrillation
_xcomplications
650 0 4 _aBenzimidazoles
_xadministration & dosage
650 0 4 _aBudgets
650 0 4 _aCost-Benefit Analysis
650 0 4 _aDabigatran
650 0 4 _aDrug Costs
650 0 4 _aDrug Substitution
_xeconomics
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMiddle Aged
650 0 4 _aSpain
650 0 4 _aStroke
_xetiology
650 0 4 _abeta-Alanine
_xadministration & dosage
700 1 _aGosalbes Sóler, Victoria
700 1 _aRidao-López, Manuel
700 1 _aNavarro Pérez, Jorge
700 1 _aNavarro Cubells, Blanca
700 1 _aPeiró, Salvador
773 0 _tRevista espanola de salud publica
_gvol. 87
_gno. 4
_gp. 331-42
856 4 0 _uhttps://doi.org/10.4321/S1135-57272013000400004
_zAvailable from publisher's website
999 _c23147733
_d23147733